Reuters
17 Jul 2026, 08:42 UTC · 1h ago
GSK to halt further development of cough drug after missing main goal
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
17 Jul 2026, 08:42 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
GSK is halting the development of its experimental drug for refractory chronic cough. — The abandonment of a late-stage drug candidate represents a loss of potential future revenue and a waste of R&D investment.
-0.40The drug failed to meet one of its primary goals in a late-stage clinical trial. — Failure in late-stage trials signals a lack of efficacy or safety, reducing confidence in the specific therapeutic pipeline.
-0.20Which stocks this story touches
The company is halting the development of an experimental drug after it failed to meet a primary goal in a late-stage trial.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
